TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ZYME

Zymeworks Inc.

Healthcare · Biotechnology

27.50$ +4.7% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Cash Flow

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Cash Flow ZYME
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
+10,939.7% -438.6% -182.1%
+19.9% +107.5% +167.2% +32.5% +102.0% +40.2% -6.8% +25.3% +44.2% -35.3% -3.6%
+142.0% +208.9% -20.1% +292.0% +264.5% -40.6% -63.1% -62.7% +101.8% +119.6% +57.6%
+62.1% -106.8% +177.4% +192.4% -41.6% -68.2% -59.3%
-205.4% +2,145.5% -83.9% -257.6% +921.6% -736.2%
+203.6% +540.6% -42.9% +9.6% +305.8% -54.9% +112.1% -1.2% -68.9% -24.8% -50.4%
+3,174.4% +176.6% +21.4% +253.0% -76.5% +69.7% -137.2% +284.9% -31.2%
+85.8%
-96.0% +3,031.8% -1.9% +58.3% -99.3% +85.8% +86.3% -32.2% +58,346.2% -103.7% +38.7%
-55.6% -212.6% -99.9% +45.5% +156.3% -58.5% -17.6% +50.0% -33.3%
-96.7% +4,172.9% -22.9% +83.0% +111.8% +59.5% -97.4% +1,255.4% -24.6% -125.0% -9.3%
-193.3% +296.7% -67.9% +1,278.0% +31.7% -135.4% -222.3%
-561.2% -193.4%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?